This is a working overview of GIP receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-19. Anything still debated is marked as such rather than presented as settled.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 39-residue peptide | GIP-derived backbone with non-natural residues |
| Molar mass | Approximately 4.8 kDa | Peptide chain plus linker and lipid modifications |
| Appearance | White to off-white powder | Typical of lyophilized research material |
| Solubility | Soluble in water and aqueous buffer | Practically insoluble in nonpolar solvents |
| Storage temperature | Typically −20 °C for dry powder | Solutions usually held at 2–8 °C short term |
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
==== New album: Criminal Migraine (2026–present) ==== On August 17, 2026, Ice-T released a new double album, Criminal Migraine, for digital download independently through his website. This is Ice's first new rap album in 20 years, since Gangsta Rap was released in 2006. The new album is not available on any streaming service and features guest appearances by Treach, Smoothe Da Hustler, CJ Mac and Ras Kass.
=== Overexpression in cancers === CUX1 is overexpressed in many cancers. The comprehensive molecular characterization of human colon and rectal cancer performed by The Cancer Genome Atlas (TCGA) ranked CUX1 as the fifth gene on a scale showing a correlation between tumour aggressiveness and gene expression/somatic copy number alterations. TCGA and REMBRANDT data also show shorter survival of glioblastoma patients with high CUX1 mRNA expression (reviewed). In smaller scale studies, immunohistochemical analyses on breast, pancreas and glioblastoma cancers reveal that CUX1 expression inversely correlates with relapse-free and overall survival. An alternative CUX1 transcript that is initiated within intron 20 and codes for a p75 isoform is expressed specifically in the testis and thymus. This transcript was found to be aberrantly expressed in many breast tumour cells lines and breast tumours. Transgenic mice expressing this transcript in mammary epithelial cells were shown to develop mammary tumours with metastasis to the lung.
Mixed by producer Paul Northfield and engineered by Terry Brown, it is a three-disc live album featuring recorded performances from the band's Counterparts, Test For Echo, and A Farewell to Kings tours, dedicated to the memory of Selena and Jacqueline. After a time of grief and recovery, and while visiting longtime Rush photographer Andrew MacNaughton in Los Angeles, Peart was introduced to his future wife, photographer Carrie Nuttall, and they married on September 9, 2000. In 2001, Peart decided to return to Rush.
=== Part II: Principles guiding foreign policy === This section briefly affirms the TGE's authority to "abide by all mutual agreements that respect the sovereignty of Ethiopia and are not contrary to the interests of the People." In addition, it grants subnational governments the right to form their own relationships with foreign organizations if it is for the purpose of humanitarian or relief efforts.
Sources: en.wikipedia.org
The analog of the poly-Pro II helix in poly-glycine is called the poly-Gly II helix. Some proteins, such as the antifreeze protein of Hypogastrura harveyi consist of bundles of glycine-rich polyglycine II helices. This remarkable protein, whose 3D structure is known, has unique NMR spectra and is stabilized by dimerization and 28 Cα-H··O=C hydrogen bonds. The PPII helix is not common in transmembrane proteins, and this secondary structure does not traverse lipid membranes in natural conditions. In 2018, a group of researchers from Germany experimentally observed the first transmembrane PPII helix formed by specifically designed artificial peptides.
Nando's opened their first outlet in New Zealand, at Glenfield in 2000. As of August 2021, there are 20 Nando's outlets throughout New Zealand, located in the regions of Auckland, Bay of Plenty, Christchurch, Hamilton, Wellington, and Dunedin. In New Zealand, Nando's sources its chicken from SPCA Certified free-range farms. However, animal welfare organisation Animals Aotearoa has raised concerns that these chickens are selectively bred to grow abnormally fast, causing chronic pain, lameness, and difficulty accessing food and water. Some reportedly suffer respiratory issues and organ failure within weeks of hatching. The organisation advocates for the Better Chicken Commitment (BCC), which Nando's UK and Ireland have adopted, but Nando's New Zealand has not, meaning unnaturally fast-growing breeds—and associated welfare issues—remain in use.
Adopted the American Experience table at its sixth convention in Buffalo, New York, in September 1920, but it wasn't until 1923 that it was actuarially sound. Headquarters in Scranton. Local groups are called "branches", and regional groups are called "Districts". National convention meets quadrennially. 20,000 members in 1930, 32,142 in 247 branches in the mid-1960s, and 31,649 in 210 branches in 1979. 30,000 members in 1994. No ritual or secrecy, but there is a pledge. Open to both sexes 16 and up. The 1979 constitution didn't say anything about Polish ancestry. Purchased Sponjnia Farm in 1929 in Waymart, Pennsylvania, and developed it into a home for aged and sick members. Began Warsaw Village in Thornhurst Township, Pennsylvania, in 1948 as summer vacation area. Helped fund Church of Our Lady of Perpetual Help near Zarki, Poland. Their first constitution declared "Religious, political and social convictions may not hinder admission", but has nevertheless been tied to the Polish National Catholic Church. Polish Roman Catholic Union of America Polish Union of America - Founded in 1890. 10,000 members in 1979. 9,000 in 1994. Active in anti-defamation campaigns, provides scholarships, contributes to churches, charities, and educational foundations; also sponsors radio broadcast. Maintains library, museum, speakers bureau, ethnic awareness programs, and vocational placement services. Also runs White Eagle Young Adults Club.
Sources: en.wikipedia.org
When the elastic fibers are relaxed the elastic chains appear disorganized, when tensile pressure is give the elastic chains appear organized and return to a disorganized state when the pressure is released. Collagen fibers form networks to provide strength and structural framework for the molecules within the extracellular matrix.
Long-term risks include mania and heart issues such as long QT syndrome, and potentially fatal interactions with other drugs. Only two randomized controlled trials have been conducted on ibogaine and noribogaine for substance use disorders, and while they show preliminary anti-addictive potential, their safety and efficacy are unconfirmed, with significant risks including cardiotoxicity and fatalities. Ibogaine is federally illegal in the United States. It is used in treatment clinics abroad under legal gray areas, with growing media attention. It has inspired the development of non-hallucinogenic, non-cardiotoxic analogues like 18-MC and tabernanthalog for therapeutic use. In 2025, Texas allocated $50 million for clinical research on ibogaine to develop FDA-approved treatments for opioid use disorder, co-occurring substance use disorders, and other ibogaine-responsive conditions. A 2026 US executive order directed federal agencies to accelerate review of ibogaine.
Much of the "medicinal" use of equid milk (donkey and mare) is based on tradition. Scientific studies on equid milk are often lacking regarding the beneficial effects for certain pathologies. Popular medicine or traditional medicine is defined as one that follows traditions or practices before the advent of industrial medicine. Many of these practices have become rooted in popular knowledge and tradition. The first written documents reporting the nutritional and "curative" effects of equine milk date back to around 2000 years ago. Herodotus in the 5th century BC mentions it as a nutritious drink. Hippocrates (460–370 BC), the father of medicine, described the medicinal virtues of donkey milk. He prescribed donkey milk for numerous ailments, such as liver problems, edemas, nosebleeds, poisonings, infectious diseases, the healing of sores, and fevers. In Roman times, donkey milk was used as a universal remedy. Pliny the Elder (23–79 AD), in his encyclopedic work Naturalis Historia, described its many health benefits, ranging from its use as an anti-venom or as a relief for external irritations (itching) to the use of it in a pomade (ointment) for the eyes. He states that donkey milk is the most effective as a medicine, followed by cow's milk, and then goat's milk. During the Renaissance, donkey milk was the subject of the first real scientific consideration when Francis I, king of France, on the advice of his doctors, used donkey milk to recover from a long illness. There are many testimonials on the effectiveness of donkey milk.
The enormous number of published literature makes it virtually impossible for individuals to read every paper, resulting in disjointed sub-fields of research. Literature analysis aims to employ computational and statistical linguistics to mine this growing library of text resources. For example:
Sources: en.wikipedia.org
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.
It is given by subcutaneous injection, generally on a weekly schedule. Dosing usually begins low and increases in steps to limit gastrointestinal side effects. Formulated product is supplied as a ready-to-use pen or vial in most markets.
No. Receptor engagement is documented, but how central appetite circuits, gut signals, and insulinotropic effects combine is incompletely resolved. Investigators continue to separate GIP-driven from GLP-1-driven contributions in animal and human models.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.